当前位置 : 首页 > 师资队伍 > 教授

闵军霞

编辑:admin 时间:2015年01月28日 访问次数:6741

闵军霞教授 

肿瘤生物学博士 博士生导师

浙江大学转化医学研究院及浙江大学附属第一医院

2014年入选浙江省海外引进高层次“浙江省千人”创新学者

个人简历:

2002-2006   肿瘤生物学 博士 美国密苏里哥伦比亚大学

2006-2010   博士后 美国哈佛大学医学院

2010-2014   诺华肿瘤制药团队负责人、新药研发课题组长及博士后导师

2014- 至今    教授、博士生导师 浙江大学转化医学研究院及附属第一医院

主要研究方向:

以中国高发肿瘤的病人基因组学大数据为出发点,探索适用于中国肿瘤病人基因型的有效新型靶向治疗、免疫治疗及克服靶向耐药的综合治疗策略。

主要成就:

多年来在美国从事肿瘤转化医学研究,在国际上首先发现鞘氨醇-1-磷酸醇(S1P)代谢通路与肿瘤化疗药物抗性关联及作用靶点;通过运用多种生物模型,系统性阐明了癌基因EZH2通过抑制抑癌基因DAB2IP,进而激活RasNF-kappa B致癌通路诱发并促使肿瘤转移的新机制,为前列腺癌诊治提供了新策略;成功领导8个肿瘤新药研发项目,研究并建立了可预测癌症化合物敏感性和预测驱动基因及通路的新型驱动网络模型;参与领导新型个体化免疫治疗,如CART19治疗B细胞恶性肿瘤。在国际著名杂志包括Nature MedicinePNASMolecularCancer Research等发表数篇原创性论文。多次受邀在国内外做大会学术报告。先后获得包括诺华科技创新奖、诺华肿瘤药物研发最佳业绩奖等一系列奖项。

获得的重要奖项

2015年 长三角绿色制药协同创新中心“特聘研究员”

2014年 浙江省海外高层次人才引进计划浙江省特聘专家

2013年 诺华优秀课题负责人奖

2012年 诺华优秀课题负责人奖

2012年 荣获诺华科技创新奖

2011年 诺华肿瘤药物研发最佳业绩奖

2006年 美国密苏里哥伦比亚大学优秀研究一等奖

国际学术会议

201586-8日:2015中国器官移植大会暨第二届中国器官移植医师年会

特邀大会报告:基于大数据的免疫细胞干预在器官移植中的转化医学研究(中国武汉)

2015522-23International Conference on Interdisciplinary Research on Long-term Care and Healthy Aging

特邀大会报告:Hallmarks of Interconnected Aging with Cancer中国杭州)

20141130-125日:第七届亚洲无机化学会议The 7th AsBIC7 Conference

特邀大会报告:Roadmap of Deregulated Iron Metabolic Pathways in Cancer

2014 622-23日:第五届中美转化医学年会The 5th Sino-American Symposium onClinical and Translational Medicine中国北京)

特邀大会报告:Translational Medicine at the Zhejiang University

2014620-21日:第四届癌症系统生物学国际研讨会 The Fourth International Workshop on Cancer Systems Biology (ICSB 2014) 中国吉林)

特邀大会报告:The power of network analysis in discovering novel cancer therapeutics

2014309-14Keystone Symposia: Inflammation, Infection and Cancer joint with the conference on Immune Evolution in Cancer(加拿大)

Poster presentation “ Identification of Tumor-Specific Splicing Isoforms in TCGA”

2013421- 26Gordon Research Conference, Cancer Genetics and Epigenetics 意大利)

Poster presentation “ DNA methylation analysis of triple-negative breast cancer”

2008527-29日:Harvard Medical School Genetics Department Retreat 美国)

大会报告:" Identifying a novel oncogenes-tumor suppressor pathway in cancer metastasis”

2008111日,MIT & DF/HCC Ludwig Center Retreat美国)

Poster presentation “ A novel tumor suppressor in prostate cancer tumorigenesis &metastasis”

20071010-12日:Colrain 20th Anniversary Meeting美国)

大会报告:"A novel tumor suppressor in prostate cancer tumorigenesis & metastasis”

20054月:EB Annual Meeting San Diego, CA (美国)

Poster Presentation “Sphingosine-1-phosphate metabolic enzymes affect the cellular response to chemotherapeutic drugs in a p38 dependent manner”

主要论著(Selected Publications *Corresponding author, 蓝色标记论文为转化院为联系单位发表文章):

1. Fang X,Wei J,He X,An P,Wang H,Jiang L,Shao D,Liang H,Li Y,Wang F*,Min J*. Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies.Eur J Cancer.2015 Dec;51(18):2820-32. doi: 10.1016/j.ejca.2015.09.010.

2. An P, Zhou D, Wang H, Wu Q, Guo X, Wu A, Zhang Z, Zhang D, Xu X, Mao Q, Shen X, Zhang L, Xiong Z, He L, Min J*, Liu Y* and Wang F*. Elevated serum transaminase activities were associated with increased serum levels of iron regulatory hormone hepcidin and hyperferritinemia risk. Scientific Reports, 2015 Aug 20;5:13106. doi: 10.1038/srep13106.

3. Fang X, Wang H, An P, Min J, and Wang F*. Cardiomyocyte-specific deletion of ferroportin using MCK-Cre has no apparent effect on either cardiac iron homeostasis. International Journal of Cardiology, 2015 Dec 15;201:90-2. doi: 10.1016/j.ijcard.2015.07.089

4. Mu M, An P, Shen X, Wu Qian, Shao D, Wang H, Zhang Y, Zhang S, Yao H, Min J*, Wang F*. The dietary flavonoid myricetin regulates iron homeostasis by suppressing hepcidin expression. Journal of Nutritional Biochemistry. 2015doi:10.1016/j.jnutbio.2015.10.015. (* co-corresponding author)

5. WANG Hong-Xiao, MIN Jun-Xia*Advances in discovering anticancer agents from plant secondary metabolitesand their derivatives,Chinese Bulletin of Life Sciences, 2015, Aug, 27(8).1006-19, DOI: 10.13376/j.cbls/2015140

6. Wu Q, Wang H, An P, Tao Y, Deng J, Zhang Z, Shen Y, Min J*, Wang F*. HJV and HFE Play Distinct Roles in Regulating Hepcidin. Antioxidants & Redox Signaling.2015 May 20;22(15):1325-36. doi: 10.1089/ars.2013.5819

7. Huang T#, Lan L#, Fang X, An P, Min J, Wang F*. Promises and Challenges of Big Data Computing in Health Sciences. Big Data Research, 2015,2, 2–11 (Invited review)

8. Zeng Y, Chen H, Ni T, Ruan R, Nie C, Liu X, Feng L, Zhang F, Lu J, Li J, Li Y, Tao W, Gottschalk W, Lutz M, Land K, Yashin AI, Tan Q, Yang Z, Bolund L, Qi M, Yang H, Min J, Willcox CD, Willcox B, Gu J, Hauser E, Tian XL, Vaupel JW. Interaction between FOXO1A-209 Genotype and Tea Drinking is Significantly Associated with Reduced Mortality at Advanced Ages. Rejuvenation Res. 2015 Sep 28.

9. Zhou Q., Derti A., Ruddy D., Rakiec D., Kao I., Lira M, Gibaja V, Chan H, Yang Y, Min J, Schlabach M, Stegmeier F. A chemical genetics approach for the functional assessment of novel cancer genes.Cancer Research.  2015 May 15;75(10):1949-58. doi: 10.1158/0008-5472.CAN-14-2930

10. Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao J. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. eLife. 2014 May 20;3:e01763. doi: 10.7554/eLife.01763.

11. Jaeger S, Min J, Nigsch F, Camargo M, Hutz, J, Cornett A, Cleaver S, Buckler A, Jenkins JL. Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer. J Biomol Screen. 2014 Feb 11;19(5):791-802 (co-first author)

12. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nature Medicine. 2010 Mar;16(3):286-94. doi: 10.1038/nm.2100.

13. Sridevi P, Alexander H, Laviad EL, Min J, Mesika A, Hannink M, Futerman AH, Alexander S. Stress-induced ER to Golgi translocation of ceramide synthase 1 is dependent on proteasomal processing. Experimental Cell Research. 2010 Jan 1;316(1):78-91. doi: 10.1016/j.yexcr.2009.09.027

14. Van Driessche N, Alexander H, Min J, Kuspa A, Alexander S, Shaulsky G. Global transcriptional responses to cisplatin in Dictyosteliumdiscoideum identify potential drug targets.Proc Natl Acad Sci U S A. 2007 Sep 25;104 (39):15406-11.

15. Min J, Mesika A, Sivaguru M, Van Veldhoven PP, Alexander H, Futerman AH, Alexander S. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Molecular Cancer Research. 2007 Aug;5(8):801-12

16. Min J, Sridevi P, Alexander S, Alexander H. Sensitive cell viability assay for use in drug screens and for studying the mechanism of action of drugs in Dictyosteliumdiscoideum. Biotechniques. 2006 Nov;41(5):591-5

17. Alexander S, Min J, Alexander H. Dictyosteliumdiscoideum to human cells: pharmacogenetic studies demonstrate a role for sphingolipids in chemoresistance. Biochim Biophys Acta. 2006 Mar;1760(3):301-9.

18. Min J, Van Veldhoven PP, Zhang L, Hanigan MH, Alexander H, Alexander S. Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner. Molecular Cancer Research. 2005 May;3(5):287-96

19. Min J, Traynor D., Stegner A.L, Zhang L., Hanigan M.H., Alexander H., and Alexander S. Sphingosine kinase regulates the sensitivity of DictyosteliumDiscoideumcells to the anticancer drug cisplatin. Eukaryotic Cell, 2005;4:178-189

20. Min J, Stegner A.L, Alexander H. and Alexander S. Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in Dictyostelium discoideum results in a selective increase in sensitivity to platinum based chemotherapy drugs. Eukaryotic Cell, 2004;3:795-805

上一篇:陆燕
下一篇:牛田野